By
Matt Koppenheffer
|
More Articles
April 28, 2011
|
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of diagnostic-test maker Gen-Probe (Nasdaq: GPRO ) rocketed up today, gaining as much as 20% in intraday trading on heavier-than-average volume.
So what: Bloomberg reported today that Gen-Probe has hired investment bank Morgan Stanley (NYSE: MS ) to manage a sale process and noted that bids are expected in the next couple of weeks. The article suggested that Novartis (NYSE: NVS ) , Thermo Fisher Scientific (NYSE: TMO ) , Danaher (NYSE: DHR ) , and Life Technologies (Nasdaq: LIFE ) could be among the bidders.
Now what: As I noted yesterday with InterMune, this kind of news tends to get traders and short-term investors very excited. However, speculation on potential buyouts can often end in disappointment if nothing ever pans out. Longer-term investors would be well-advised to continue focusing on the prospects for Gen-Probe as a stand-alone company and leave the rumors to the traders.
Want to keep up to date on these stocks?